NASDAQ Biotechnology Stock
Genta Incorporated also referred to herein as ‘‘us’’, ‘‘we’’, ‘‘our’’, ‘‘Genta’’ or ‘‘the Company’’, was incorporated in Delaware on February 4, 1988. Genta is a biopharmaceutical company engaged in pharmaceutical (drug) research and development, its sole reportable ...
more
We are a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Our lead products are: REVLIMID(R) (lenalidomide), which was approved by the U.S. Food and Drug Administration, or FDA, in June 2006 for treatment in combination with dexamethasone for multiple ...
more
JDS Uniphase Corporation (“JDSU”) is a worldwide leading provider of innovative broadband and optical products and solutions that enable dramatic improvements in the way we communicate, detect, present, and
experience information. Our products are used in communications, commercial and consumer applications including broadband and optical networks, brand protection, biotechnology, ...
more
AtheroGenics is a research-based pharmaceutical company incorporated in the State of Georgia
in 1993. We are focused on the discovery, development and commercialization of novel drugs for the
treatment of chronic inflammatory diseases, including coronary heart disease, organ transplant
rejection, rheumatoid arthritis and asthma. We have developed a proprietary ...
more
This annual report on
Form 10-K contains
forward-looking statements that involve risks and uncertainties.
Forward-looking statements include statements about our product
development and commercialization goals and expectations,
potential market opportunities, our plans for and anticipated
results of our clinical development activities and the potential ...
more
We
are an early-stage biotech company that focuses on discovering and developing new
drugs that address critical unmet medical needs in the areas of thrombocytopenia, cancer, hepatitis
C, hormone-related diseases, osteoporosis and inflammatory diseases. We strive to develop drugs
that are more effective and/or safer than existing therapies, that are more ...
more
Encysive Pharmaceuticals Inc. is a global biopharmaceutical company that engages in the
discovery, development and commercialization of novel, synthetic, small molecule compounds to
address unmet medical needs. We focus our research and development programs predominantly on the
treatment and prevention of interrelated diseases of the vascular endothelium and ...
more
We exclusively licensed
Angiomax from Biogen Idec, Inc. in 1997 and we have exclusive license rights to
develop, market and sell Angiomax worldwide. We received our first marketing
approval from the U.S. Food and Drug Administration, or the FDA, in December 2000
for Angiomax for use as an anticoagulant in combination with aspirin in
patients with unstable angina undergoing percutaneous ...
more
We have included or incorporated by
reference into this Annual Report on Form 10-K statements that may constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by
words including “anticipate,” “believe,” “intends,” “estimates,” ...
more
We expect to continue to operate at a loss, we may not be able to maintain our current levels of research, development and commercialization
activities, and we may never achieve profitability.
more
We are a biopharmaceutical company focused on discovering,
developing and commercializing innovative therapies for severe or life-threatening illnesses. We currently market and sell products in the acute-care hospital setting in the United States and Canada. We also receive royalties and other revenues
through licensing agreements with numerous biotechnology and pharmaceutical companies based ...
more
Cubist Pharmaceuticals, Inc.
, which we refer to as “Cubist” or the “Company”, is a biopharmaceutical
company focused on the research, development and commercialization of
pharmaceutical products that address unmet medical needs in the acute care
environment. To date, we have concentrated exclusively on developing products
for the antiinfective marketplace.
more
We incorporated in March 1991
as a California corporation and changed our state of incorporation to Delaware
in May 1997. Our executive offices are located at 4140 Dublin Blvd., Suite 200,
Dublin, CA, 94568 and our telephone number at that address is (925) 560-0100.
We maintain a website on the internet at
www.supergen.com. This is a textual reference only. We do not ...
more
We are a biopharmaceutical company exploiting
proprietary RNA-based drug discovery technologies to create a new class of
drugs to treat important diseases. RNA, or ribonucleic acid, is a molecule that
provides to a cell the information the cell needs to produce proteins,
including those proteins associated with disease. Interference with RNA can
keep the body from producing the proteins that ...
more
Prescription
drugs are playing a greater role in healthcare and today constitute the first
line of treatment for many medical conditions. As pharmaceutical research opens
the potential for even more effective drugs, demand can be expected to increase.
For millions of people, prescription drugs equate to the hope of improved health
and quality of life. At the same ...
more
